J Ryan Mark, Leonard G Gomella, Costas D Lallas, Katherine E Smentkowski, Anne Calvaresi, Nathan Handley, Robert B Den, Patrick Mille, William J Tester, Jean Hoffman-Censits, Adam P Dicker, Edward Klonicke, Ethan Halpern, Peter McCue, W Kevin Kelly, Edouard J Trabulsi
{"title":"通过多学科临床方法加强膀胱癌的治疗。","authors":"J Ryan Mark, Leonard G Gomella, Costas D Lallas, Katherine E Smentkowski, Anne Calvaresi, Nathan Handley, Robert B Den, Patrick Mille, William J Tester, Jean Hoffman-Censits, Adam P Dicker, Edward Klonicke, Ethan Halpern, Peter McCue, W Kevin Kelly, Edouard J Trabulsi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>To report the impact of our 25-year multidisciplinary care delivery model experience on patients with muscle invasive bladder cancer treated at our National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center at Jefferson University. To our knowledge, our multidisciplinary genitourinary cancer clinic (MDC) is the longest continuously operating center of its kind at an NCI Cancer Center in the United States.</p><p><strong>Materials and methods: </strong>We selected a recent group of patients with cT2-4 N0-1 M0 bladder cancer seen in the Sidney Kimmel Cancer Center Genitourinary Oncology MDC from January 2016 to September 2019. These patients were identified retrospectively. SEER-18 (Surveillance, Epidemiology, and End Results) database, November 2019 submission was queried to obtain patients with similarly staged disease diagnosed between 2015 and 2017. Completion rates of radical cystectomy, use of neoadjuvant therapies, and survival outcomes were compared between the two cohorts.</p><p><strong>Results: </strong>Ninety-one patients from the MDC form this time period were identified; 65.9% underwent radical cystectomy and 71.8% received neoadjuvant therapy in the form of chemotherapy, immune checkpoint inhibition or a combination of the two - higher than reported national trends for neoadjuvant therapies. Progression of disease was seen in 24.2% of patients. A total of 8675 patients met inclusion criteria in the SEER database. Rates of radical cystectomy were significantly higher in MCD patients when compared to SEER derived data (65.9% vs. 37.7%, p =< 0.001). MCD patients had significantly better cancer-specific survival (mean 20.4 vs. 18.3 months p = 0.028, median survival not reached).</p><p><strong>Conclusion: </strong>Our long term experience caring for patients with genitourinary malignancies such as bladder cancer in a uniform multidisciplinary team results in a high utilization of neoadjuvant therapies. When compared to a contemporary SEER-derived cohort, multidisciplinary patients were more likely to undergo radical cystectomy and had longer cancer-specific survival.</p>","PeriodicalId":56323,"journal":{"name":"Canadian Journal of Urology","volume":"30 3","pages":"11526-11531"},"PeriodicalIF":1.2000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Enhancing bladder cancer care through the multidisciplinary clinic approach.\",\"authors\":\"J Ryan Mark, Leonard G Gomella, Costas D Lallas, Katherine E Smentkowski, Anne Calvaresi, Nathan Handley, Robert B Den, Patrick Mille, William J Tester, Jean Hoffman-Censits, Adam P Dicker, Edward Klonicke, Ethan Halpern, Peter McCue, W Kevin Kelly, Edouard J Trabulsi\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>To report the impact of our 25-year multidisciplinary care delivery model experience on patients with muscle invasive bladder cancer treated at our National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center at Jefferson University. To our knowledge, our multidisciplinary genitourinary cancer clinic (MDC) is the longest continuously operating center of its kind at an NCI Cancer Center in the United States.</p><p><strong>Materials and methods: </strong>We selected a recent group of patients with cT2-4 N0-1 M0 bladder cancer seen in the Sidney Kimmel Cancer Center Genitourinary Oncology MDC from January 2016 to September 2019. These patients were identified retrospectively. SEER-18 (Surveillance, Epidemiology, and End Results) database, November 2019 submission was queried to obtain patients with similarly staged disease diagnosed between 2015 and 2017. Completion rates of radical cystectomy, use of neoadjuvant therapies, and survival outcomes were compared between the two cohorts.</p><p><strong>Results: </strong>Ninety-one patients from the MDC form this time period were identified; 65.9% underwent radical cystectomy and 71.8% received neoadjuvant therapy in the form of chemotherapy, immune checkpoint inhibition or a combination of the two - higher than reported national trends for neoadjuvant therapies. Progression of disease was seen in 24.2% of patients. A total of 8675 patients met inclusion criteria in the SEER database. Rates of radical cystectomy were significantly higher in MCD patients when compared to SEER derived data (65.9% vs. 37.7%, p =< 0.001). MCD patients had significantly better cancer-specific survival (mean 20.4 vs. 18.3 months p = 0.028, median survival not reached).</p><p><strong>Conclusion: </strong>Our long term experience caring for patients with genitourinary malignancies such as bladder cancer in a uniform multidisciplinary team results in a high utilization of neoadjuvant therapies. When compared to a contemporary SEER-derived cohort, multidisciplinary patients were more likely to undergo radical cystectomy and had longer cancer-specific survival.</p>\",\"PeriodicalId\":56323,\"journal\":{\"name\":\"Canadian Journal of Urology\",\"volume\":\"30 3\",\"pages\":\"11526-11531\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Urology","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
简介:报告我们25年多学科护理模式对在美国国家癌症研究所(NCI)指定的杰斐逊大学Sidney Kimmel癌症中心治疗的肌肉浸润性膀胱癌患者的影响。据我们所知,我们的多学科泌尿生殖系统癌症诊所(MDC)是美国NCI癌症中心同类中持续运营时间最长的中心。材料和方法:我们选择了2016年1月至2019年9月在Sidney Kimmel癌症中心生殖泌尿肿瘤MDC看到的近期一组cT2-4 N0-1 M0膀胱癌患者。对这些患者进行回顾性鉴定。对2019年11月提交的SEER-18(监测、流行病学和最终结果)数据库进行了查询,以获取2015年至2017年间诊断出类似分期疾病的患者。比较两组患者的根治性膀胱切除术的完成率、新辅助治疗的使用和生存结果。结果:91例患者从这一时期的MDC形式确定;65.9%的人接受了根治性膀胱切除术,71.8%的人接受了化疗、免疫检查点抑制或两者结合的新辅助治疗,高于全国新辅助治疗的趋势。24.2%的患者出现疾病进展。共有8675名患者符合SEER数据库的纳入标准。与SEER数据相比,MCD患者根治性膀胱切除术的发生率明显更高(65.9% vs. 37.7%, p =< 0.001)。MCD患者的癌症特异性生存期明显更好(平均20.4个月vs. 18.3个月p = 0.028,中位生存期未达到)。结论:我们在统一的多学科团队中护理泌尿生殖系统恶性肿瘤(如膀胱癌)患者的长期经验导致新辅助治疗的高使用率。与当代seer衍生的队列相比,多学科患者更有可能接受根治性膀胱切除术,癌症特异性生存期更长。
Enhancing bladder cancer care through the multidisciplinary clinic approach.
Introduction: To report the impact of our 25-year multidisciplinary care delivery model experience on patients with muscle invasive bladder cancer treated at our National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center at Jefferson University. To our knowledge, our multidisciplinary genitourinary cancer clinic (MDC) is the longest continuously operating center of its kind at an NCI Cancer Center in the United States.
Materials and methods: We selected a recent group of patients with cT2-4 N0-1 M0 bladder cancer seen in the Sidney Kimmel Cancer Center Genitourinary Oncology MDC from January 2016 to September 2019. These patients were identified retrospectively. SEER-18 (Surveillance, Epidemiology, and End Results) database, November 2019 submission was queried to obtain patients with similarly staged disease diagnosed between 2015 and 2017. Completion rates of radical cystectomy, use of neoadjuvant therapies, and survival outcomes were compared between the two cohorts.
Results: Ninety-one patients from the MDC form this time period were identified; 65.9% underwent radical cystectomy and 71.8% received neoadjuvant therapy in the form of chemotherapy, immune checkpoint inhibition or a combination of the two - higher than reported national trends for neoadjuvant therapies. Progression of disease was seen in 24.2% of patients. A total of 8675 patients met inclusion criteria in the SEER database. Rates of radical cystectomy were significantly higher in MCD patients when compared to SEER derived data (65.9% vs. 37.7%, p =< 0.001). MCD patients had significantly better cancer-specific survival (mean 20.4 vs. 18.3 months p = 0.028, median survival not reached).
Conclusion: Our long term experience caring for patients with genitourinary malignancies such as bladder cancer in a uniform multidisciplinary team results in a high utilization of neoadjuvant therapies. When compared to a contemporary SEER-derived cohort, multidisciplinary patients were more likely to undergo radical cystectomy and had longer cancer-specific survival.